Recent Biotech IPO’s; (ASND), (ENTL), (FLKS), (ONCE), (TCON), (ZSAN)
Point Roberts WA, NEW YORK, NY – February 3, 2015 -
Investorideas.com, a global news source covering leading sectors including biotech
and medical technology stocks reports on the recent IPO’s in the sector. The
flood of IPO’s is making experts ask if a biotech bubble is being created. With
up to 100 IPO’s in the works for this year, time will tell.
Here is a look at some of the recent listings:
Ascendis Pharma (NASDAQ:ASND) completed its initial
public offering of 6,900,000 American Depositary Shares (ADSs) at a price to
the public of $18.00 per ADS. The stock is currently trading at $19.04. Ascendis
Pharma A/S is a clinical stage biopharmaceutical company applying its TransCon
technology to develop a pipeline of long-acting prodrug therapies with
best-in-class profiles to address large markets with significant unmet medical
needs.
Entellus Medical Inc (NASDAQ:ENTL) began trading on The
NASDAQ Stock Market on January 29, 2015. The IPO consisted of 4,603,580 shares
of its common stock at an initial public offering price of $17.00 per share
Entellus is a medical technology company focused on the design, development and
commercialization of products for the minimally invasive treatment of patients
in the physician office setting or operating room who are suffering from
chronic sinusitis. The XprESS family of products is used by ear, nose and
throat, or ENT, physicians to open narrowed or obstructed sinus drainage
pathways using balloon sinus dilation to treat patients with symptomatic
inflammation of the nasal sinuses. The stock is currently trading at $21.52.
On January 28th Flex Pharma Inc (NASDAQ: FLKS) announced its initial
public offering of 5,400,000 shares of common stock at a public offering price
of $16.00 per share. Flex Pharma, Inc. is a biopharmaceutical company that is
developing innovative and proprietary treatments for nocturnal leg cramps and
spasms associated with severe neuromuscular conditions.
January 30th Spark Therapeutics Inc (NASDAQ:ONCE) announced its offering of 7,000,000 shares of
common stock at a public offering price of $23.00 per share, before
underwriting discounts. Spark is
a late clinical-stage gene therapy company seeking to develop one-time,
life-altering treatments for debilitating genetic diseases, with an initial
focus on treating rare diseases. Spark's most advanced product candidate,
SPK-RPE65, which has received both breakthrough therapy and orphan product
designation, is in a fully-enrolled pivotal Phase 3 clinical trial for the
treatment of a rare blinding condition. Spark also has product candidates in
development for the treatment of additional blinding conditions, hematologic
disorders and neurodegenerative diseases. The stock is trading at $45.82 this
morning.
TRACON Pharmaceuticals Inc (NASDAQ:TCON) IPO consisted of 3,600,000
shares of common stock at a price to the public of $10.00 per share. TRACON
develops targeted therapies for cancer, age‐related macular degeneration
and fibrotic diseases. TRACON’s current pipeline includes two clinical stage
product candidates: TRC105, an antiendoglin antibody that is being developed
for the treatment of multiple solid tumor types, and TRC102, a small molecule
that is being developed for the treatment of lung cancer and glioblastoma. Both
TRC105 and TRC102 are being developed for treatment in combination with
currently available therapies. The stock is currently trading below its IPO
price.
Zosano Pharma Corp (NASDAQ:ZSAN) completed its
offering of 4,500,000 shares of common stock at a price to the public of $11.00
per share. The stock is trading at $11.06 in this morning’s session. Zosano
Pharma Corporation is a clinical stage specialty pharmaceutical company that
has developed a proprietary transdermal microneedle patch system to deliver its
proprietary formulations of existing drugs through the skin for the treatment
of a variety of indications. Zosano's microneedle patch system offers rapid onset,
consistent drug delivery, improved ease of use and room-temperature stability,
benefits that the company believes often are unavailable using oral
formulations or injections. Zosano's microneedle patch system has the potential
to deliver numerous medications for a wide variety of indications in
commercially attractive markets. It has been tested in more than 400 patients
with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2
clinical studies.
InvestorIdeas.com newswire is a global recognized news source. We
publish original content, third party investment commentary, contributor
articles, company news and press releases in leading sectors.
Sectors we cover in include
mining, energy, renewable energy, water stocks, food and beverage (including
organic and LOHAS, wine), defense and security, biotech, technology and mobile.
We have also recently expanded our global coverage to include Latin American
stocks, sports and entertainment.
Sign up for free news alerts at
Investorideas.com
Become an Investorideas.com Member and access our online stock
directories listing thousands of publicly traded stocks in leading sectors
Disclaimer/ Disclosure: The Investorideas.com newswire is a
third party publisher of news and research as well as creates original content
as a news source. Original content created by investorideas is protected by
copyright laws other than syndication rights. Investorideas is a news source on
Google news syndication partners. Our site does not make recommendations for
purchases or sale of stocks or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated by featured companies, news submissions, content
marketing and online advertising. Contact each company directly for press
release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15
2008 - all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
Contact
Investorideas.com
800 665 0411
No comments:
Post a Comment